232 related articles for article (PubMed ID: 33344548)
1. No significant association between dipeptidyl peptidase-4 inhibitors and adverse outcomes of COVID-19.
Zhou JH; Wu B; Wang WX; Lei F; Cheng X; Qin JJ; Cai JJ; Zhang XJ; Zhou F; Liu YM; Li HM; Zhu LH; She ZG; Zhang X; Yang J; Li HL
World J Clin Cases; 2020 Nov; 8(22):5576-5588. PubMed ID: 33344548
[TBL] [Abstract][Full Text] [Related]
2. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
Ou HT; Chang KC; Li CY; Wu JS
Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
[TBL] [Abstract][Full Text] [Related]
3. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis.
Mui JV; Zhou J; Lee S; Leung KSK; Lee TTL; Chou OHI; Tsang SL; Wai AKC; Liu T; Wong WT; Chang C; Tse G; Zhang Q
Front Cardiovasc Med; 2021; 8():747620. PubMed ID: 34746262
[No Abstract] [Full Text] [Related]
4. Disentangling conflicting evidence on DPP-4 inhibitors and outcomes of COVID-19: narrative review and meta-analysis.
Bonora BM; Avogaro A; Fadini GP
J Endocrinol Invest; 2021 Jul; 44(7):1379-1386. PubMed ID: 33512688
[TBL] [Abstract][Full Text] [Related]
5. Use of DPP4i reduced odds of clinical deterioration and hyperinflammatory syndrome in COVID-19 patients with type 2 diabetes: Propensity score analysis of a territory-wide cohort in Hong Kong.
Wong CKH; Lui DTW; Lui AYC; Kwok ACY; Low MCH; Lau KTK; Au ICH; Xiong X; Chung MSH; Lau EHY; Cowling BJ
Diabetes Metab; 2022 Jan; 48(1):101307. PubMed ID: 34863934
[TBL] [Abstract][Full Text] [Related]
6. Dipeptidyl peptidase-4 inhibitor use and mortality in COVID-19 patients with diabetes mellitus: an updated systematic review and meta-analysis.
Pal R; Banerjee M; Mukherjee S; Bhogal RS; Kaur A; Bhadada SK
Ther Adv Endocrinol Metab; 2021; 12():2042018821996482. PubMed ID: 33680425
[TBL] [Abstract][Full Text] [Related]
7. Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study.
Wong CKH; Man KKC; Shi M; Chan EW; Ho CW; Tse ETY; Wong ICK; Lam CLK
PLoS Med; 2019 Dec; 16(12):e1002999. PubMed ID: 31877127
[TBL] [Abstract][Full Text] [Related]
8. Dipeptidyl peptidase-4 inhibitor use is not associated with elevated risk of severe joint pain in patients with type 2 diabetes: a population-based cohort study.
Hou WH; Chang KC; Li CY; Ou HT
Pain; 2016 Sep; 157(9):1954-1959. PubMed ID: 27127847
[TBL] [Abstract][Full Text] [Related]
9. Association Between DPP4 Inhibitor Use and the Incidence of Cirrhosis, ESRD, and Some Cancers in Patients With Diabetes.
Na Y; Kim SW; Park IB; Choi SJ; Nam S; Jung J; Lee DH
J Clin Endocrinol Metab; 2022 Nov; 107(11):3022-3034. PubMed ID: 36108097
[TBL] [Abstract][Full Text] [Related]
10. Association between dipeptidyl peptidase-4 inhibitors and risk of bullous pemphigoid in patients with type 2 diabetes: A population-based cohort study.
Wu CY; Wu CY; Li CP; Chou YJ; Lin YH; Chang YT
Diabetes Res Clin Pract; 2021 Jan; 171():108546. PubMed ID: 33232759
[TBL] [Abstract][Full Text] [Related]
11. Dipeptidyl peptidase-4 inhibitor compared with sulfonylurea in combination with metformin: cardiovascular and renal outcomes in a propensity-matched cohort study.
Kim KJ; Choi J; Lee J; Bae JH; An JH; Kim HY; Yoo HJ; Seo JA; Kim NH; Choi KM; Baik SH; Kim SG; Kim NH
Cardiovasc Diabetol; 2019 Mar; 18(1):28. PubMed ID: 30857540
[TBL] [Abstract][Full Text] [Related]
12. COVID-19 and comorbidities: A role for dipeptidyl peptidase 4 (DPP4) in disease severity?
Bassendine MF; Bridge SH; McCaughan GW; Gorrell MD
J Diabetes; 2020 Sep; 12(9):649-658. PubMed ID: 32394639
[TBL] [Abstract][Full Text] [Related]
13. Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan.
Chang CY; Yeh YH; Chan YH; Liu JR; Chang SH; Lee HF; Wu LS; Yen KC; Kuo CT; See LC
Cardiovasc Diabetol; 2017 Dec; 16(1):159. PubMed ID: 29258504
[TBL] [Abstract][Full Text] [Related]
14. Dipeptidyl peptidase 4 inhibitor use is associated with a lower risk of incident acute kidney injury in patients with diabetes.
Chao CT; Wang J; Wu HY; Chien KL; Hung KY
Oncotarget; 2017 Aug; 8(32):53028-53040. PubMed ID: 28881791
[TBL] [Abstract][Full Text] [Related]
15. Dipeptidyl-Peptidase 4 Inhibitors did not Improve Renal Endpoints in Advanced Diabetic Kidney Disease.
Kornelius E; Huang CN; Lo SC; Wang YH; Yang YS
Endocr Pract; 2020 Dec; 26(12):1486-1496. PubMed ID: 33471741
[TBL] [Abstract][Full Text] [Related]
16. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis.
Min SH; Yoon JH; Hahn S; Cho YM
Diabetes Metab Res Rev; 2017 Jan; 33(1):. PubMed ID: 27155214
[TBL] [Abstract][Full Text] [Related]
17. Dipeptidyl peptidase-4 inhibitors lower the risk of autoimmune disease in patients with type 2 diabetes mellitus: A nationwide population-based cohort study.
Seong JM; Yee J; Gwak HS
Br J Clin Pharmacol; 2019 Aug; 85(8):1719-1727. PubMed ID: 30964554
[TBL] [Abstract][Full Text] [Related]
18. Association Between Glucagon-Like Peptide 1 Receptor Agonist and Sodium-Glucose Cotransporter 2 Inhibitor Use and COVID-19 Outcomes.
Kahkoska AR; Abrahamsen TJ; Alexander GC; Bennett TD; Chute CG; Haendel MA; Klein KR; Mehta H; Miller JD; Moffitt RA; Stürmer T; Kvist K; Buse JB;
Diabetes Care; 2021 Jul; 44(7):1564-1572. PubMed ID: 34135013
[TBL] [Abstract][Full Text] [Related]
19. The effects of DPP4 inhibitors on the levels of plasma catecholamines and their metabolites in patients with type 2 diabetes.
Kim TH; Lee K; Park IB; Choi CS; Ahn TH; Lee DH
Diabetes Res Clin Pract; 2019 Oct; 156():107832. PubMed ID: 31513823
[TBL] [Abstract][Full Text] [Related]
20. Bullous Pemphigoid Associated with Dipeptidyl Peptidase 4 Inhibitors for the Treatment of Type 2 Diabetes: A Multicenter Study in Istanbul.
Ugurer E; Ozkur E; Altunay IK; Sen EC; Aksu AEK; Ozcan I; Altuntas Y; Gurel MS
Sisli Etfal Hastan Tip Bul; 2022; 56(3):375-380. PubMed ID: 36304224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
